Recent News 5 : Finally An Article From The World Health Organization on Phages !

Bacteriophages and Antimicrobial Resistance: Why Phage Therapy Could Transform Modern Medicine

Antimicrobial resistance is now considered one of the greatest medical and public health challenges of the twenty-first century. As bacteria continue to evolve mechanisms that render antibiotics ineffective, healthcare systems around the world are facing infections that are increasingly difficult, and sometimes impossible, to treat. The rise of multidrug-resistant pathogens has revived scientific interest in an older but remarkably sophisticated biological tool: bacteriophages.

Bacteriophages, often simply called phages, are viruses that infect bacteria with extraordinary specificity. They are the most abundant biological entities on Earth, naturally present in oceans, soils, rivers, wastewater, plants, animals, and even within the human microbiome. For billions of years, phages have participated in a continuous evolutionary struggle with bacteria, shaping microbial ecosystems and regulating bacterial populations across virtually every environment on the planet.

Unlike conventional antibiotics, which broadly target bacterial processes and often disrupt beneficial microbial communities, phages recognize specific bacterial receptors and infect only selected bacterial strains. This precision has become one of the most compelling arguments in favor of phage therapy, particularly in an era dominated by antimicrobial resistance.

The concept of using phages therapeutically is not new. Phages were first discovered independently by Frederick Twort in 1915 and Félix d’Hérelle in 1917, long before the widespread introduction of antibiotics. During the early twentieth century, phage therapy was explored in several countries as a treatment for bacterial infections. However, the rapid success of antibiotics after World War II led most Western countries to abandon phage research. In contrast, countries in Eastern Europe and the former Soviet Union continued developing phage-based medicine for decades, particularly in Georgia and Poland, where specialized institutes accumulated extensive clinical experience treating chronic and resistant infections.

Today, the global antimicrobial resistance crisis has forced modern medicine to reconsider phages not as historical curiosities, but as potential precision antimicrobials capable of addressing infections that no longer respond to conventional drugs.

Phages used in medicine are generally lytic phages. After attaching to a susceptible bacterium, the phage injects its genetic material into the bacterial cell and hijacks the host’s molecular machinery to produce new viral particles. Once replication is complete, the bacterial cell is lysed, releasing newly formed phages that can infect neighboring bacteria. This self-amplifying mechanism distinguishes phage therapy from antibiotics, whose concentration progressively decreases after administration.

One of the greatest scientific advantages of phages lies in their specificity. Because they target defined bacterial species or even particular strains, they can eliminate pathogenic bacteria while preserving commensal microbiota. This is particularly important given the growing recognition that disruption of the human microbiome contributes to numerous complications, including opportunistic infections, metabolic disorders, and immune dysregulation.

Phage therapy has generated particular interest for the treatment of infections caused by multidrug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacterales. Several compassionate-use cases reported over the past decade have demonstrated successful outcomes in patients suffering from severe infections unresponsive to antibiotics. In some instances, phages have been administered intravenously, topically, or directly into infected tissues, leading to bacterial clearance where conventional therapies had failed.

Researchers are also increasingly interested in the synergistic relationship between phages and antibiotics. Experimental studies suggest that combining phages with antimicrobial agents can enhance bacterial eradication while simultaneously reducing the probability of resistance emergence. Certain antibiotics may even sensitize bacteria to phage infection by altering bacterial surface structures or metabolic pathways. Conversely, phage pressure can force bacteria to evolve resistance mechanisms that reduce their virulence or restore sensitivity to antibiotics.

Despite this promise, phage therapy remains scientifically and clinically complex. Unlike broad-spectrum antibiotics, phages cannot universally target all bacterial infections. Each phage is highly specific, meaning clinicians must identify the causative bacterium and select appropriate active phages before treatment can begin. This often requires access to specialized phage libraries and advanced microbiological diagnostics. Moreover, not all naturally occurring phages possess suitable therapeutic properties. Some may exhibit insufficient lytic activity, instability during manufacturing, or unfavorable interactions with the host immune system.

Bacterial resistance to phages also represents an important biological challenge. Just as bacteria evolve resistance to antibiotics, they can develop mechanisms to evade phage infection through receptor modification, CRISPR-Cas systems, or restriction enzymes. However, the evolutionary dynamics between phages and bacteria differ fundamentally from those observed with antibiotics. Phages themselves evolve continuously, potentially allowing the development of adaptive therapeutic strategies in which phage cocktails are periodically updated to overcome emerging bacterial resistance.

The safety profile of phage therapy appears generally favorable, particularly because phages do not infect human cells. Nevertheless, therapeutic administration is not entirely without risks. Rapid bacterial lysis may trigger the release of endotoxins and inflammatory mediators, especially during treatment of severe Gram-negative infections. Furthermore, regulatory authorities remain cautious regarding manufacturing consistency, genomic characterization, and quality control of biological phage preparations.

Another major obstacle concerns regulation itself. Modern pharmaceutical systems were designed around chemically stable drugs manufactured according to fixed formulations. Phages challenge this paradigm because they are living biological entities requiring individualized adaptation to specific bacterial infections. Personalized phage cocktails, while scientifically promising, do not fit easily into traditional regulatory frameworks for medicinal products. Consequently, phage therapy in most Western countries remains restricted largely to compassionate use programs or experimental clinical trials.

Beyond human medicine, phages are increasingly studied within the broader One Health framework, which recognizes the interconnected relationship between human, animal, and environmental health. In veterinary medicine, phages may reduce antibiotic use in livestock by treating bacterial diseases without contributing significantly to antimicrobial resistance selection pressure. In agriculture, phages are already used experimentally to control bacterial pathogens affecting crops such as tomatoes, peppers, potatoes, apples, and pears. In aquaculture, phages may offer alternatives to the extensive antibiotic use currently associated with fish farming.

Environmental applications are also attracting scientific attention. Researchers are exploring phage-based strategies for hospital surface decontamination, wastewater treatment, and reduction of antimicrobial-resistant bacterial reservoirs in environmental settings. Because environmental dissemination plays a critical role in the spread of resistance genes, phages could eventually contribute not only to treatment but also to prevention and ecological control of resistant pathogens.

The future of phage therapy will depend largely on the quality of clinical evidence generated over the coming years. Although individual case reports and early clinical studies remain encouraging, large-scale randomized controlled trials are still limited. Scientists must establish standardized protocols for phage selection, manufacturing, dosing, administration routes, pharmacokinetics, and monitoring of bacterial resistance. Advances in synthetic biology, genomics, artificial intelligence, and personalized medicine may accelerate this process by enabling rapid identification and engineering of optimized therapeutic phages.

As antimicrobial resistance continues to threaten global healthcare systems, phages represent one of the most biologically sophisticated alternatives currently under investigation. They are not a universal replacement for antibiotics, nor a miraculous solution capable of eliminating all resistant infections. However, their unique evolutionary relationship with bacteria offers medicine a fundamentally different therapeutic paradigm: one based not on static chemical inhibition, but on dynamic biological adaptation.

The renewed scientific interest in phage therapy reflects a broader shift in modern medicine toward precision microbiology and ecosystem-based approaches to infectious disease. In a world where antibiotics are progressively losing their effectiveness, bacteriophages may once again become indispensable allies in humanity’s ongoing struggle against bacterial pathogens.

Sources : https://www.who.int/europe/news-room/fact-sheets/item/bacteriophages-and-their-use-in-combating-antimicrobial-resistance